Medpace (NASDAQ:MEDP) Now Covered by Wolfe Research

Equities researchers at Wolfe Research started coverage on shares of Medpace (NASDAQ:MEDP) in a research note issued to investors on Tuesday, April 2nd, The Fly reports. The firm set an “outperform” rating on the stock.

A number of other research analysts have also issued reports on MEDP. ValuEngine lowered Medpace from a “buy” rating to a “hold” rating in a research report on Thursday, December 6th. BidaskClub lowered Medpace from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, December 18th. Zacks Investment Research lowered Medpace from a “buy” rating to a “hold” rating in a research report on Wednesday, January 9th. Finally, TheStreet lowered Medpace from a “b” rating to a “c” rating in a research report on Friday, March 22nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. Medpace currently has a consensus rating of “Buy” and a consensus price target of $55.33.

Shares of NASDAQ MEDP traded up $0.86 during trading on Tuesday, reaching $58.71. The stock had a trading volume of 234,790 shares, compared to its average volume of 642,650. Medpace has a one year low of $35.00 and a one year high of $71.66. The company has a current ratio of 0.69, a quick ratio of 0.69 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $2.10 billion, a price-to-earnings ratio of 22.67, a price-to-earnings-growth ratio of 1.81 and a beta of 1.62.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, February 25th. The company reported $0.76 EPS for the quarter, topping the Zacks’ consensus estimate of $0.69 by $0.07. The firm had revenue of $192.12 million during the quarter, compared to the consensus estimate of $184.66 million. Medpace had a return on equity of 17.66% and a net margin of 11.27%. The firm’s revenue was up 70.5% on a year-over-year basis. During the same period in the prior year, the business earned $0.39 EPS. As a group, equities analysts predict that Medpace will post 2.64 earnings per share for the current year.

In other news, General Counsel Stephen P. Ewald sold 7,946 shares of the business’s stock in a transaction on Friday, March 29th. The stock was sold at an average price of $57.95, for a total transaction of $460,470.70. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO August J. Troendle sold 4,221 shares of the business’s stock in a transaction on Monday, January 28th. The stock was sold at an average price of $61.04, for a total value of $257,649.84. Following the sale, the chief executive officer now directly owns 603,702 shares in the company, valued at $36,849,970.08. The disclosure for this sale can be found here. In the last 90 days, insiders sold 566,049 shares of company stock valued at $36,097,951. Insiders own 24.20% of the company’s stock.

A number of large investors have recently bought and sold shares of the stock. LS Investment Advisors LLC acquired a new position in Medpace in the 4th quarter worth about $46,000. SHANDA ASSET MANAGEMENT HOLDINGS Ltd bought a new stake in shares of Medpace during the 4th quarter worth about $87,000. State of Alaska Department of Revenue bought a new stake in shares of Medpace during the 4th quarter worth about $92,000. NumerixS Investment Technologies Inc bought a new stake in shares of Medpace during the 4th quarter worth about $119,000. Finally, We Are One Seven LLC bought a new stake in shares of Medpace during the 4th quarter worth about $130,000. 82.88% of the stock is currently owned by hedge funds and other institutional investors.

Medpace Company Profile

Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.

Further Reading: What causes a recession?

The Fly

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.